Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
- Fonarow GC, Corday E. Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report From the ADHERE Registry. Heart Fail Rev. 2004l;9(3):179-185.
- Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in Patients With Heart Failure and Preserved Ejection Fraction. N Engl J Med. 2008;359(23):2456-2467.
- Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure With Preserved Ejection Fraction. N Engl J Med. 2014;370(15):1383-1392.
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of Candesartan in Patients With Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781.
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure With a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.
Disclosure statements are available on the authors' profiles: